Detalles de la búsqueda
1.
Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States.
Adv Ther
; 40(3): 1153-1170, 2023 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-36648737
2.
Q-TWiST analysis of pembrolizumab combined with chemotherapy as first-line treatment of metastatic triple-negative breast cancer that expresses PD-L1.
Eur J Cancer
; 177: 45-52, 2022 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-36323052
3.
Efficacy and safety of losartan in children with Alport syndrome--results from a subgroup analysis of a prospective, randomized, placebo- or amlodipine-controlled trial.
Nephrol Dial Transplant
; 26(8): 2521-6, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21285125
4.
Effects of odanacatib on BMD and safety in the treatment of osteoporosis in postmenopausal women previously treated with alendronate: a randomized placebo-controlled trial.
J Clin Endocrinol Metab
; 98(12): 4727-35, 2013 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-24064689
5.
Odanacatib in the treatment of postmenopausal women with low bone mineral density: five years of continued therapy in a phase 2 study.
J Bone Miner Res
; 27(11): 2251-8, 2012 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-22777865
6.
A fast exchange algorithm for designing focused libraries in lead optimization.
J Chem Inf Model
; 45(3): 758-67, 2005.
Artículo
en Inglés
| MEDLINE | ID: mdl-15921465
Resultados
1 -
6
de 6
1
Próxima >
>>